On May 20, Smoore International fell 3.12% in regular trading, trading at HK$9.96 per share, with trading volume of HK$71.26 million.

The decline represents a continued technical pullback following a sustained rally earlier this month. The US FDA's first-ever approval of non-tobacco flavored e-cigarettes through PMTA review had previously driven Smoore International's stock price up over 20% within the month, with multiple sessions of gains exceeding 5%. Since May 14, the stock has pulled back on consecutive trading days as profit-taking pressure mounted.

Institutional analysts maintain a constructive medium-to-long-term view on the company, noting that FDA regulatory direction is focused on cracking down on illegal products while easing restrictions on compliant flavored products. Smoore International, as a global core atomization equipment supplier, has developed underage identification technology considered a key factor in FDA approval decisions. Core client products and proprietary brands are expected to accelerate through the approval process, directly benefiting from the recovery of the compliant market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)